Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.34 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.34 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.34 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044056 | 1.00 | HIF1A (0.39) | HIF1AP2RX7SCN2ASCN10AKMT2A | |
| SCHEMBL8750824 | 0.88 | HIF1A (0.40) | HIF1AP2RX7SCN2ASCN10AKMT2A | |
| SCHEMBL8750839 | 0.87 | P2RX7 (0.41) | HIF1AP2RX7SCN2ASCN10AKMT2A | |
| SCHEMBL8750762 | 0.86 | HIF1A (0.46) | HIF1AP2RX7SCN2ASCN10AKMT2A | |
| SCHEMBL8750780 | 0.86 | HIF1A (0.39) | HIF1AP2RX7SCN2ASCN10AKMT2A | |
| SCHEMBL8750783 | 0.85 | P2RX7 (0.38) | HIF1AP2RX7SCN2ASCN10AKMT2A | |
| SCHEMBL8750759 | 0.84 | KDM4E (0.41) | HIF1AP2RX7SCN2ASCN10AKMT2A | |
| SCHEMBL8750825 | 0.83 | P2RX7 (0.41) | HIF1AP2RX7SCN2ASCN10AKMT2A | |
| SCHEMBL8750822 | 0.83 | P2RX7 (0.37) | HIF1AP2RX7SCN2ASCN10AKMT2A | |
| SCHEMBL8750753 | 0.83 | P2RX7 (0.48) | HIF1AP2RX7KMT2ACNR1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732534-B1 | USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS | SERONO LAB (CH) | 2008-07-23 | — | — | EP | claimed |
| EP-0956866-A1 | DRUGS FOR AMELIORATING OPHTHALMIC CIRCULATORY DISTURBANCE | KIRIN BEER KABUSHIKI KAISHA (JP) | 1999-11-17 | — | — | EP | claimed |
| EP-0634400-B1 | PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF | KIRIN BREWERY (JP) | 1997-04-02 | — | — | EP | claimed |
| US-5508293-A | TREATING HYPERTENSION, ANGINA PECTORIS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1996-04-16 | — | — | US | claimed |
| EP-0634400-A1 | PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF | KIRIN BEER KABUSHIKI KAISHA (JP) | 1995-01-18 | — | — | EP | claimed |
| JP-8165239-A | — | — | None | — | — | JP | disclosed |
| EP-1663239-A4 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS SINAI MEDICAL CENTER (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1663239-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| WO-2005025511-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2005-03-24 | — | — | WO | disclosed |
| EP-0956866-A1 | DRUGS FOR AMELIORATING OPHTHALMIC CIRCULATORY DISTURBANCE | KIRIN BEER KABUSHIKI KAISHA (JP) | 1999-11-17 | — | — | EP | disclosed |
| WO-1998035673-A1 | DRUGS FOR RELIEVING PERIPHERAL CIRCULATION DISORDER | KIRIN BEER KABUSHIKI KAISHA (JP) | 1998-08-20 | — | — | WO | disclosed |
| EP-0634400-B1 | PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF | KIRIN BREWERY (JP) | 1997-04-02 | — | — | EP | disclosed |
| JP-H08165239-A | ANTI-ARTERIOSCLEROTIC AGENT | KIRIN BREWERY CO LTD | 1996-06-25 | — | — | JP | disclosed |
| US-5508293-A | TREATING HYPERTENSION, ANGINA PECTORIS | KIRIN BEER KABUSHIKI KAISHA (JP) | 1996-04-16 | — | — | US | disclosed |
| EP-0634400-A1 | PYRIDINECARBOXIMIDAMIDE COMPOUND AND USE THEREOF | KIRIN BEER KABUSHIKI KAISHA (JP) | 1995-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | HIF1A 387/4885P2RX7 411/4885SCN2A 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.